Petros Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036
Mailing Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036
Phone
973-242-0005
Fiscal Year End
1231
EIN
851410058
Financial Overview
FY2025
$1.91M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | April 15, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 8-K Current report of material events | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 7, 2025 | View on SEC |
| 8-K Current report of material events | September 5, 2025 | View on SEC |
Annual Reports
10-K
April 15, 2026
- Complete pivot from pharmaceutical sales to healthcare technology software licensing.
- Eliminated legacy debt by divesting prescription drug and medical device assets.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.